INmune Bio's (INMB) Neutral Rating Reaffirmed at BTIG Research

INmune Bio (NASDAQ:INMB - Get Free Report)'s stock had its "neutral" rating restated by investment analysts at BTIG Research in a research note issued to investors on Tuesday, MarketBeat reports.

Separately, Scotiabank restated a "sector underperform" rating on shares of INmune Bio in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $22.80.

INmune Bio Stock Performance

Shares of INmune Bio stock traded down $0.22 during midday trading on Tuesday, reaching $2.09. 8,749,893 shares of the company's stock traded hands, compared to its average volume of 734,736. INmune Bio has a 52 week low of $1.91 and a 52 week high of $11.64. The company's 50 day simple moving average is $7.32 and its 200 day simple moving average is $7.34. The company has a market cap of $48.03 million, a price-to-earnings ratio of -1.08 and a beta of 1.55.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting analysts' consensus estimates of ($0.43). The company had revenue of $0.05 million for the quarter. As a group, equities research analysts predict that INmune Bio will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On INmune Bio

Several large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its position in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after purchasing an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new stake in INmune Bio during the fourth quarter worth about $48,000. Quarry LP acquired a new stake in INmune Bio during the first quarter worth about $48,000. JPMorgan Chase & Co. increased its stake in INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after acquiring an additional 5,461 shares during the period. Finally, Two Sigma Advisers LP acquired a new position in INmune Bio in the 4th quarter valued at approximately $59,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.